Being A Biomedical Entrepreneur - Growth Of The Biomedical Industry


Book Description

This book is about the great innovations that the biomedical industry has had on improving the health and treating diseases of people and the incredible effort that scientists, engineers, technologists, mathematicians and physicians has invested in conceptualizing, producing and marketing the innovations. This rapidly growing industry is a knowledge intensive industry that is constantly generating, and adapting to, new technology. The innovations are the movers leading to the growth of the biomedical industry since 1960. However, its growth may be threatened by the lack of access to capital, a burdensome and uncertain regulatory environment, and lack of R&D innovation and productivity.It is written for students and professionals in science, technology, engineering, mathematics and medicine wanting to become a successful biomedical entrepreneur and to grow the biomedical industry. This book covers these four sectors of biomedical industries: medical technologies, healthcare information technology, pharmaceutic industry and biotech.Many innovations are employed throughout the book to make this book as a resource of use to help you invent, evaluate, develop and market your innovative products. Part I examines the education merits of biomedical engineers and teaches biomedical professionals to conceptualize their innovations and to assess whether their innovations could be manufactured and be wanted by patients. Part II will guide budding entrepreneurs to form the company and entrepreneurial team, to raise venture capital, to patent your innovative products, to obtain regulatory approval and to write your business plan. Other important aspects of company operations like financing, negotiations, leadership, manufacturing, marketing and globalization are covered in Part III. Two concluding chapters, with excerpts from leaders in community, education and industries, touch on the development, growth and investment of biomedical entrepreneurs on the delivery of better healthcare and economy to all people in the world.




Pharmaceutical and Biomedical Project Management in a Changing Global Environment


Book Description

Pharmaceutical and Biomedical Portfolio Management in a Changing Global Environment explores some of the critical forces at work today in the complex endeavour of pharmaceutical and medical product development. Written by experienced professionals, and including real-world approaches and best practice examples, this new title addresses three key areas – small molecules, large molecules, and medical devices - and provides hard-to-find, consolidated information relevant to and needed by pharmaceutical, biotech, and medical device company managers.




Biotech Industry


Book Description

"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.




Beyond Technonationalism


Book Description

The biomedical industry, which includes biopharmaceuticals, genomics and stem cell therapies, and medical devices, is among the fastest growing worldwide. While it has been an economic development target of many national governments, Asia is currently on track to reach the epicenter of this growth. What accounts for the rapid and sustained economic growth of biomedicals in Asia? To answer this question, Kathryn Ibata-Arens integrates global and national data with original fieldwork to present a conceptual framework that considers how national governments have managed key factors, like innovative capacity, government policy, and firm-level strategies. Taking China, India, Japan, and Singapore in turn, she compares each country's underlying competitive advantages. What emerges is an argument that countries pursuing networked technonationalism (NTN) effectively upgrade their capacity for innovation and encourage entrepreneurial activity in targeted industries. In contrast to countries that engage in classic technonationalism—like Japan's developmental state approach—networked technonationalists are global minded to outside markets, while remaining nationalistic within the domestic economy. By bringing together aggregate data at the global and national level with original fieldwork and drawing on rich cases, Ibata-Arens telegraphs implications for innovation policy and entrepreneurship strategy in Asia—and beyond.




Beyond Borders


Book Description




Biotechnology in the Time of COVID-19


Book Description

47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity.




Technological Systems in the Bio Industries


Book Description

Technological Systems in the Bio Industries: An International Study represents a comprehensive, interdisciplinary, and systematic effort to understand the nature and role of technological change in a rapidly evolving arena of economic activity that can be loosely referred to as the bio industries. These include biomedical industries that deliver goods and services used in health care, including those based on genetic engineering, as well as applications of biotechnology in other industries such as agriculture, food production, and the forest industries. This volume is the third in a continuing series of studies on technological systems; it seeks to identify and address new sets of conceptual and methodological issues in analyzing innovation systems, particularly as regards the delimitation of relevant systems. The book makes an in-depth comparison of the biomedical clusters in Sweden and Ohio. It also sheds light on the emergence of new science-based technological systems.




Capitalizing on New Needs and New Opportunities


Book Description

This report addresses a topic of recognized policy concern. To capture the benefits of substantial U.S. investments in biomedical R&D, parallel investments in a wide range of seemingly unrelated disciplines are also required. This report summarizes a major conference that reviewed our nation's R&D support for biotechnology and information technologies. The volume includes newly commissioned research and makes recommendations and findings concerning the important relationship between information technologies and biotechnology. It emphasizes the fall off in R&D investments needed to sustain the growth of the U.S. economy and to capitalize on the growing investment in biomedicine. It also encourages greater support for inter-disciplinary training to support new areas such as bioinformatics and urges more emphasis on and support for multi-disciplinary research centers.




From Breakthrough to Blockbuster


Book Description

"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--